No abstract

OBJECTIVE: Hypertension is a major modifiable risk factor for cardiovascular disease and premature death worldwide. Phoenixin is a newly identified neuropeptide with multiple bioactivity. However, there was no published data about phoenixin levels in hypertension. The aim of this study was to evaluate the relationship between phoenixin and hypertension. METHODS: This study was performed in 36 patients with hypertension and 36 healthy controls. Serum phoenixin-14 and phoenixin-20 levels were determined by Enzyme-Linked ImmunoSorbent Assay method. RESULTS: Serum phoenixin-14 and phoenixin-20 values were significantly lower in hypertension patients compared with the control group (p<0.001). The levels of phoenixin-14 were negatively correlated with weight (r=-0.376; p<0.005), body mass index (r=-0.407; p<0.001), systolic blood pressure (r=-0.586; p<0.001), and diastolic blood pressure (r=-0.319; p<0.01). There was a negative correlation between serum phoenixin-20 and weight (r=-0.378; p<0.005), body mass index (r=-0.383; p<0.005), systolic blood pressure (r=-0.551; p<0.001), and diastolic blood pressure (r=-0.306; p<0.01). We used receiver operating characteristic curve analyses to compare the diagnosis value of Phoenixin-14 and Phoenixin-20 levels in hypertensive patients. We found that Phoenixin-14 value is an area under the curve of 0.87 (cutoff value 404.7 ng/L, sensitivity 92%, specificity 72%) and Phoenixin-20 value is an area under the curve of 0.83 (cutoff value 209.9 ng/L, sensitivity 86%, specificity 75%). Phoenixin-14 did nearly show equally compared to phoenixin-20 in predicting hypertension. CONCLUSION: Serum phoenixin-14 and phoenixin-20 may be related to the pathogenesis of hypertension. Our findings indicated that serum phoenixin-14 and phoenixin-20 may serve as a novel biomarker for the diagnosis of hypertension.

No abstract

Introduction: Ectopic pancreatic tissue (EP) occurs in the gastrointestinal tract at a rate of 95%, usually detected incidentally. Pediatric cases have been reported rarely. Here, we present the patients who were detected during the endoscopic procedure. Methods: Between 2015-2018, 485 patients who underwent esophagogastroduodenoscopy in two different centers were evaluated retrospectively in this study. Results: During the procedure, the lesion was detected in 14 patients (eight boys and six girls), which could be macroscopically compatible with ectopic pancreatic tissue. The age range of the patients was 12.3±4.1 years. Eleven of the lesions were localized in the pre-pyloric antrum and one of them was located in the distal esophagus. Histopathological examination revealed ectopic pancreatic tissue in the esophagus biopsy specimen and in six of the antrum biopsy specimens. Discussion and Conclusion: EP is usually asymptomatic, commonly detected in the gastrointestinal tract (esophagus, stomach, duodenum, jejunum, ileum, omentum, gallbladder, Meckel's diverticulum) and can be seen in all age groups. The gold standard for diagnosis is histopathological evaluation. There are few case reports in the pediatric age group. In our series, we found the incidence of EP to be 1%. AbstractCorrespondence (İletişim): Esra Polat, M.D. Ilhan Varank Egitim ve Arastirma Hastanesi, Cocuk Gastroenterolojisi Klinigi, İstanbul, Turkey Phone (Telefon): +90 505 550 01 70

Aim:The susceptibility to gastrointestinal bleeding is observed with an increase in altitude. There is no recommendation regarding altitude in terms of drug selection and dose to be used in diseases requiring antiaggregant and anticoagulant use. In this study, we aimed to determine whether there is a difference between gastrointestinal bleeding requiring hospitalization due to the use of antiaggregant and/or anticoagulant therapy between two populations living at different altitudes. Material and Method: This retrospective study was performed in two secondary care hospitals. Patients from Group B living in villages with an altitude of 9842 ft and above and Group F patients living in an area with an altitude of 30 ft were included. Patient's demographic data, co-morbid diseases, antiaggregant and anticoagulant use, hemoglobin, hematocrit, MCV values and platelet count were noted. Results:The study included a total of 118 patients with gastrointestinal bleeding. There was no statistically significant difference between the groups in terms of the drugs used by the patients, the types and numbers of drugs. Conclusion: We found that there was no significant difference between the groups with different altitudes in terms of drugs used by patients with gastrointestinal bleeding, drug types and numbers.